Baseline characteristics and enrichment results from the SONAR trial

Diabetes, Obesity and Metabolism

Volumn 20, Issue 8, 2018, Pages 1829-1835

  Heerspink, Hiddo J L ^a   Andress, Dennis L ^b   Bakris, George ^c   Brennan, John J ^b   Correa Rotter, Ricardo ^d   Hou, Fan Fan ^e   Kitzman, Dalane W ^f   Kohan, Donald ^g   Makino, Hirofumi ^h   McMurray, John ⁱ   Perkovic, Vlado ^j   Tobe, Sheldon ^k   Wigderson, Melissa ^b   Yi, Tingting ^b   Parving, Hans Henrik ^l,m   de Zeeuw, Dick ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b ABBVIE INC   (United States)

^c UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

^d National Institute for Medica Sciences and Nutrition Salvador Zubiran   (Mexico)

^e SOUTHERN MEDICAL UNIVERSITY   (China)

^f WAKE FOREST SCHOOL OF MEDICINE   (United States)

^g UNIVERSITY OF UTAH HEALTH SCIENCES CENTER   (United States)

^h OKAYAMA UNIVERSITY   (Japan)

ⁱ UNIVERSITY OF GLASGOW   (United Kingdom)

^j UNIVERSITY OF NEW SOUTH WALES   (Australia)

^k NORTHERN ONTARIO SCHOOL OF MEDICINE   (Canada)

^l UNIVERSITY OF COPENHAGEN   (Denmark)

^m AARHUS UNIVERSITY   (Denmark)

more..

Author keywords

atrasentan; diabetic kidney disease; endothelin receptor antagonist; precision medicine; randomized controlled clinical trial

Indexed keywords

ATRASENTAN; BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENDOTHELIN A RECEPTOR ANTAGONIST;

ADULT; ALBUMINURIA; ARTICLE; BODY WEIGHT GAIN; CARDIOVASCULAR DISEASE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIABETIC NEPHROPATHY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; ENRICHMENT DESIGN; ESTIMATED GLOMERULAR FILTRATION RATE; FEMALE; FLUID RETENTION; HIGH RISK POPULATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; RANDOMIZED CONTROLLED TRIAL; RENAL PROTECTION; RENAL SYSTEM PARAMETERS; SEVERE RENAL IMPAIRMENT; SODIUM RETENTION; STUDY DESIGN; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION; URINARY ALBUMIN TO CREATININE RATIO; AGED; CLINICAL TRIAL; COMBINATION DRUG THERAPY; COMPLICATION; DIABETIC ANGIOPATHY; DRUG RESISTANCE; GLOMERULUS FILTRATION RATE; HYPERTENSION; KIDNEY FAILURE; PERSONALIZED MEDICINE; RISK;

AGED; ANGIOTENSIN RECEPTOR ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; ATRASENTAN; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; DIABETIC NEPHROPATHIES; DIURETICS; DOUBLE-BLIND METHOD; DRUG RESISTANCE; DRUG THERAPY, COMBINATION; ENDOTHELIN A RECEPTOR ANTAGONISTS; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; PRECISION MEDICINE; RENAL INSUFFICIENCY; RISK;

EID: 85046739578     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/dom.13315     Document Type: Article

References (15)

1. de Zeeuw D, Heerspink HJ. Unmet need in diabetic nephropathy: failed drugs or trials? Lancet Diabetes Endocrinol. 2016;4:638-640
2. de Zeeuw D, Heerspink HJL, Jardine M, Perkovic V. Renal trials in diabetes need a platform: time for a global approach? Lancet Diabetes Endocrinol. 2017 [Epub ahead of print]. https://doi.org/10.1016/S2213-8587(17)30263-2
3. Heerspink HJL, Andress DL, Bakris G, et al. Rationale and protocol of the Study of Diabetic Nephropathy with Atrasentan (SONAR) trial: a clinical trial design novel to diabetic nephropathy. Diabetes Obes Metab. 2018. https://doi.org/10.1111/dom.13245. [Epub ahead of print]
4. Kohan DE, Pritchett Y, Molitch M, et al. Addition of atrasentan to renin-angiotensin system blockade reduces albuminuria in diabetic nephropathy. J Am Soc Nephrol. 2011;22:763-772
5. de Zeeuw D, Coll B, Andress D, et al. The endothelin antagonist atrasentan lowers residual albuminuria in patients with type 2 diabetic nephropathy. J Am Soc Nephrol. 2014;25:1083-1093
6. Parving HH, Brenner BM, McMurray JJ, et al. Baseline characteristics in the Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE). J Renin Angiotensin Aldosterone Syst. 2012;13:387-393
7. Fried LF, Emanuele N, Zhang JH, et al. Combined angiotensin inhibition for the treatment of diabetic nephropathy. N Engl J Med. 2013;369:1892-1903
8. Dhaun N, MacIntyre IM, Kerr D, et al. Selective endothelin-A receptor antagonism reduces proteinuria, blood pressure, and arterial stiffness in chronic proteinuric kidney disease. Hypertension. 2011;57:772-779
9. Dhaun N, Macintyre IM, Melville V, et al. Blood pressure-independent reduction in proteinuria and arterial stiffness after acute endothelin-A receptor antagonism in chronic kidney disease. Hypertension. 2009;54:113-119
10. Kohan D, Heerspink HJL, Coll B, et al. Atrasentan-associated fluid retention in patients with diabetic nephropathy: predictive markers and impact on albuminuria reduction. Clin J Am Soc Nephrol. 2015;10:1568-1574
11. Heerspink HJ, Johnsson E, Gause-Nilsson I, et al. Dapagliflozin reduces albuminuria in patients with diabetes and hypertension receiving renin-angiotensin blockers. Diabetes Obes Metab. 2016;18:590-597
12. Petrykiv S, Sjostrom CD, Greasley PJ, Xu J, Persson F, HJL H. Differential effects of dapagliflozin on cardiovascular risk factors at varying degrees of renal function. Clin J Am Soc Nephrol. 2017;12:751-759
13. Cherney DZI, Zinman B, Inzucchi SE, et al. Effects of empagliflozin on the urinary albumin-to-creatinine ratio in patients with type 2 diabetes and established cardiovascular disease: an exploratory analysis from the EMPA-REG OUTCOME randomised, placebo-controlled trial. Lancet Diabetes Endocrinol. 2017;5:610-621
14. Wanner C, Inzucchi SE, Lachin JM, et al. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med. 2016;375:323-334
15. Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377:644-657